Reports Q1 revenue $49.9M, consensus $20.47M. ImmunoGen had $201.2M in cash and cash equivalents as of March 31, , compared with $275.1M as of December 31, 2022. "With a strong Q1 of sales and continued momentum in FRalpha testing and market access, we have started the year making great strides towards establishing ELAHERE as the standard of care for FRalpha-positive ovarian cancer," said Mark Enyedy, ImmunoGen’s President and Chief Executive Officer. "Our commercial and medical teams have delivered exemplary performances in the first stages of the ELAHERE launch and we look forward to continued success with the appointment of Isabel Kalofonos as our new Chief Commercial Officer."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IMGN:
- ImmunoGen Rockets Up on Great Sales, Earnings
- ImmunoGen names Isabel Kalofonos as Chief Commercial Officer
- JPMorgan SMid cap biotech analyst to hold analyst/industry conference call
- Sutro transferred with Equal Weight from Overweight at Wells Fargo
- Immunogen confident in early Elahere launch, says Guggenheim
